Bortezomib will boost the amount or impact of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Greater flibanserin adverse effects could manifest if coadministered with a number of weak CYP3A4 inhibitors. Acute progress or exacerbation of congestive coronary heart failure and new onset of lowered remaining ventricular https://benjaminf444rco6.mybuzzblog.com/profile